Enjoy this snapshot of notable CCTS achievements toward our mission of transforming clinical and translational research to improve health across the Partner Network region and beyond.

i2b2 enabled self-service access to clinical data for 277 unique users in 2017, up from 110 in 2016.
CCTS - Minority 2
CCTS has contributed to the training of 380 grads, postdocs, and jr. faculty in health disparities research—70% from underrepresented minority groups.
Making a Difference - Steve Rowe
Making a Difference: The first cystic fibrosis (CF) patient in the world to receive ivacaftor (drug proven to be successful in CF treatment) was treated at the CCTS research unit in 2012 by Dr. Steve Rowe, Co-Director of the CCTS Child Health Research Unit, who has since led the team in demonstrating additional effectiveness with dual and triple-drug treatment combinations that may work for up to 90% of all CF patients.
CHIA awardees have leveraged their awards to secure more than $350,000 in matching funds and additional in-kind support and have served over 300,000 people in our community.
CCTS Informatics
CCTS Informatics enabled 375 downloads of detailed data sets in 2017.
More than 2,000 trained via games on CCTS Kaizen training platform.
CCTS Research Training Program
More than 300 research team members from across the CCTS Partner Network have completed the CCTS Research Training Program since 2013.
Making a Difference - Courtney Peterson
Making a Difference: CCTS KL2 Scholar Courtney Peterson, PhD, Assistant Professor, UAB Dept. of Nutrition Sciences, conducted the first studies of early time-restricted feeding (eTRF) in humans to better understand the impact of meal timing and circadian rhythms on obesity, diabetes, and cardiovascular disease. Her findings, including that eTRF reverses or prevents diabetes and insulin resistance and improves blood pressure and oxidative stress as well, have been featured in Science Daily, the New York Times, the Washington Post, and News Medical and on NBC News and the Today Show.
Undiagnosed Diseases Program (UDP)
Fifty-seven of the 160 patients evaluated by our Undiagnosed Diseases Program (UDP) have been successfully diagnosed.
Partner - Pilot Program
Partner pilot project proposals grew from 7% to 40% of all applications received in just two years.
Project Panels
CCTS has conducted nearly 1,000 panels over the past five years, significantly enhancing investigator success in funding.
Pilot Projects
CCTS pilot project manuscripts are cited an average of 5.7x more frequently than the median NIH-funded paper in the respective field.
Pilot Program
CCTS has awarded 62 pilot projects, producing 1,467 publications and a 49:1 ROI, since inception.
Eight multisite projects initiated in less than a year, with more in the pipeline.
i2b2 2
CCTS i2b2 offers 18 types of data from 1 million patients and 149 million lab results—and still growing!
Making a Difference - Harold Amos Awardees
Making a Difference: CCTS is the only CTSA in the network to have two Harold Amos Medical Faculty Development Program Scholars: Latesha Elopre, MD, MSPH, Assistant Professor, UAB Division of Infectious Diseases, and Greg Payne, MD, PhD, Fellow, UAB Division of Cardiovascular Disease. Dr. Elopre seeks to reduce barriers to the use of PrEP among African American women at high risk for contracting HIV. Dr. Payne’s research on the novel mechanisms of inflammation in cardiovascular disease may lead to fewer cardiac transplant rejections. Both scholars received CCTS panels to strengthen their applications.
I-Corps Nationals
The CCTS is leading nine CTSA Hubs charged by NCATS to develop a translational version of the National Science Foundation’s I-Corps™ program. The I-Corps@NCATS training has launched at the CCTS Hub and Partner Network region. The goal is to prepare biomedical scientists and engineers to think “translationally” about their science and ensure they are developing research projects that address real-world health needs.
Making a Difference - Lucio Miele
Making a Difference: An international team co-led by CCTS Partner Network Site Lead Lucio Miele, MD, PhD, has discovered genetic mutations that promote survival of cancer cells. The study, published in PLOS ONE, focused testing on genes in 44 cancers that no longer respond to therapy. The team found the cancers had evolved new “driver” mutations that impart resistance. The mutations exist in functional pathways that can be targeted with existing drugs, enabling a precision medicine approach to treatment.
CCTS is collaborating with two CTSA Hubs (UMass and Vanderbilt) to develop and test novel methods for improving the informed consent process. Strengthening Translational Research in Diverse Enrollment (STRIDE) features a REDCap-based eConsent platform that uses avatars and videos of real participants sharing research experiences to increase trust and interest in clinical trials.
Making a Difference - Anthony C. Hood
Making a Difference: CCTS One Great Community CoChair and UAB Collat School of Business Associate Professor of Strategic Management and Entrepreneurship Anthony C. Hood, PhD, received Alabama Power’s 2018 Power of Leadership Award for his community engagement work to prepare minority youth and women for STEM careers and entrepreneurship. Dr. Hood will attend the Young American Leaders Program at Harvard Business School this summer.
Special Topics in Clinical Trials
More than 550 research team members attended our bimonthly research seminars in 2017.